Head-to-head evidence
HB0017 vs UA026
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-17A · full Psoriasis pipeline
HB0017
Developed by Huabo Biopharm Co.
NCT06477237 · Phase 3 · status unknown
This is a randomized, quadruple-blind, placebo-controlled Phase 3 trial using validated psoriasis response measures as its primary endpoints, but no results are yet posted to the registry, so the outcome is unknown.
UA026
Developed by Usynova Pharmaceuticals Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HB0017's landscape · UA026's landscape